CTRL Therapeutics
2 employees
Biotech
Seed · $10.0M
Company details
Team Size2
IndustryBiotech
Funding
Total raised
$10.0M
Last stage
Seed
Investors
FACIT
Total raised
$10.0M
Last stage
Seed
Investors
Derrell Porter
MD with over 20 years of biopharma experience; formerly founder and CEO of Cellevolve Bio; held leadership roles at Atara Bio, Gilead Sciences, AbbVie, Amgen, and McKinsey & Company; sits on the boards of Passage Bio and Acumen Pharma.
Shana Kelley
Ph.D. scientist and co-founder of CTRL Therapeutics; developed the proprietary microfluidic/magnetic cell-sorting platform (IsoQore) for isolating circulating tumor-reactive lymphocytes from blood; technology licensed from the University of Toronto.
No applications, no recruiter spam. Just the intro.
A few questions to make sure this role is the right shape for you. Two minutes.
I write the intro, send it to the founder, and handle the back-and-forth.
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.